Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells

International Journal of Molecular Medicine

Volumn 32, Issue 2, 2013, Pages 503-510

  Hou, Guo Qing ^a   Guo, Chun ^b   Song, Guo Hua ^b   Fang, Na ^c   Fan, Wen Juan ^b   Chen, Xu Dong ^b   Yuan, Lei ^b   Wang, Zhen Quan ^b  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b Luohe Medical College   (China)

^c HENAN UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Lipopolysaccharide; Mitogen activated protein kinases; Osteoclasts; Receptor activator of nuclear factor B

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTIBIOTIC AGENT; CARBONATE DEHYDRATASE II; CATHEPSIN K; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ARTICLE; BONE DESTRUCTION; CELL VIABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE 2; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; LIPOPOLYSACCHARIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOCLASTS; PHOSPHORYLATION; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84879398299     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1406     Document Type: Article

References (39)

1. Roodman D: Advances in bone biology: The osteoclast. Endocr Rev 17: 308-332, 1996.
2. Nair SP, Meghji S, Wilson M, Reddi K, White P and Henderson B: Bacterially induced bone destruction: Mechanisms and misconceptions. Infect Immun 64: 2371-2380, 1996. (Pubitemid 26226792)
3. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999. (Pubitemid 30649812)
4. Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature 423: 337-342, 2003. (Pubitemid 40852708)
5. Shuto T, Jimi E, Kukita T, Hirata M and Koga T: Granulocytemacrophage colony stimulating factor suppresses lipopolysaccharide-induced osteoclast-like cell formation in mouse bone marrow cultures. Endocrinology 134: 831-837, 1994. (Pubitemid 24057230)
6. Abu-Amer Y, Ross FP, Edwards J and Teitelbaum SL: Lipopolysaccharide- stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 100: 1557-1565, 1997. (Pubitemid 27425783)
7. Islam S, Hassan F and Tumurkhuu G, et al: Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 macrophage cells. Biochem Biophys Res Commun 360: 346-351, 2007. (Pubitemid 47030351)
8. Mörmann M, Thederan M, Nackchbandi I, Giese T, Wagner C and Hänsch GM: Lipopolysaccharides (LPS) induce the differentiation of human monocytes to osteoclasts in a tumour necrosis factor (TNF) alpha-dependent manner: A link between infection and pathological bone resorption. Mol Immunol 45: 3330-3337, 2008.
9. Itoh K, Udagawa N, Kobayashi K, et al: Lipopolysaccharide promotes the survival of osteoclasts via toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J Immunol 170: 3688-3695, 2003. (Pubitemid 36359239)
10. Takami M, Kim N, Rho J and Choi Y: Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol 169: 1516-1523, 2002. (Pubitemid 34809198)
11. Orcel P, Feuga M, Bielakoff J and De Vernejoul MC: Local bone injections of LPS and M-CSF increase bone resorption by different pathways in vivo in rats. Am J Physiol 264: E391-E397, 1993. (Pubitemid 23103951)
12. Chiang CY, Kyritsis G, Graves DT and Amar S: Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infect Immun 67: 4231-4236, 1999. (Pubitemid 29357050)
13. Ito HO, Shuto T, Takada H, Koga T, Aida Y, Hirata M and Koga T: Lipopolysaccharides from Porphyromonas gingivalis, Prevotella intermedia and Actinobacillus actinomycetemcomitans promote osteoclastic differentiation in vitro. Arch Oral Biol 41: 439-444, 1996. (Pubitemid 27061182)
14. Guo C, Hou GQ, Li XD, et al: Quercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cells. Cell Physiol Biochem 30: 123-136, 2012.
15. Halleen JM, Raisanen S, Salo JJ, et al: Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 274: 22907-22910, 1999.
16. Angel NZ, Walsh N, Forwood MR, Ostrowski MC, Cassady AI and Hume DA: Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J Bone Miner Res 15: 103-110, 2000. (Pubitemid 30026937)
17. Reponen P, Sahlberg C, Munaut C, Thesleff I and Tryggvason K: High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 124: 1091-1102, 1994. (Pubitemid 24109410)
18. Yu X, Huang Y, Collin-Osdoby P and Osdoby P: Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 18: 1404-1418, 2003. (Pubitemid 41070795)
19. Wilson SR, Peters C, Saftig P and Brömme D: Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 284: 2584-2592, 2009.
20. Ishikawa T, Kamiyama M, Tani-Ishii N, et al: Inhibition of osteoclast differentiation and bone resorption by cathepsin K antisense oligonucleotides. Mol Carcinog 32: 84-91, 2001.
21. Kozloff KM, Quinti L, Patntirapong S, Hauschka PV, Tung CH, Weissleder R and Mahmood U: Non-invasive optical detection of cathepsin K-mediated fluorescence reveals osteoclast activity in vitro and in vivo. Bone 44: 190-198, 2009.
22. Lehenkari P, Hentunen TA, Laitala-Leinonen T, Tuukkanen J and Väänänen HK: Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+. Exp Cell Res 242: 128-137, 1998. (Pubitemid 28366528)
23. Li L, Pettit AR, Gregory LS and Forwood MR: Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): A rose by any other name. Cytokine Growth Factor Rev 17: 203-216, 2006. (Pubitemid 43816896)
24. Ono K, Akatsu T, Murakami T, et al: Involvement of cyclooxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 17: 774-781, 2002. (Pubitemid 34441893)
25. Ono K, Akatsu T, Kugai N, Pilbeam CC and Raisz LG: The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines. Bone 33: 798-804, 2003. (Pubitemid 37393491)
26. Kellinsalmi M, Parikka V, Risteli J, et al: Inhibition of cyclooxygenase-2 down-regulates osteoclast and osteoblast differentiation and favours adipocyte formation in vitro. Eur J Pharmacol 572: 102-110, 2007. (Pubitemid 47429646)
27. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D and Dougall WC: A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 277: 44347-44356, 2002. (Pubitemid 36157870)
28. Crockett JC, Mellis DJ, Scott DI and Helfrich MH: New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: Focus on the RANK/RANKL axis. Osteoporos Int 22: 1-20, 2011.
29. Kong YY, Yoshida H, Sarosi I, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323, 1999.
30. Kim N, Odgren PR, Kim DK, Marks SC Jr and Choi Y: Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 97: 10905-10910, 2000.
31. Li J, Sarosi I, Yan XQ, et al: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97: 1566-1571, 2000. (Pubitemid 30118482)
32. Dougall WC, Glaccum M, Charrier K, et al: RANK is essential for osteoclast and lymph node development. Genes Dev 13: 2412-2424, 1999. (Pubitemid 29453612)
33. Feeley BT, Liu NQ, Conduah AH, et al: Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and RANK:Fc administration. J Bone Miner Res 21: 1571-1580, 2006. (Pubitemid 44484602)
34. Childs LM, Paschalis EP, Xing L, et al: In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 17: 192-199, 2002. (Pubitemid 34087651)
35. Kim H, Choi HK, Shin JH, et al: Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J Clin Invest 119: 813-825, 2009.
36. Poblenz AT, Jacoby JJ, Singh S and Darnay BG: Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides. Biochem Biophys Res Commun 359: 510-515, 2007. (Pubitemid 46898981)
37. Pearson G, Robinson F, Beers Gibson T, et al: Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev 22: 153-183, 2001. (Pubitemid 32458157)
38. Zhang W and Liu HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12: 9-18, 2002. (Pubitemid 135708299)
39. Pedram A, Razandi M and Levin ER: Extracellular signalregulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 273: 26722-26728, 1998. (Pubitemid 28471688)